Results 181 to 190 of about 15,740 (203)

Venetoclax

Reactions Weekly, 2019
  +7 more sources

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Cancers, 2022
Jeroen Janssen, David C De Leeuw, Smit Linda   +2 more
exaly  

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Hematological Oncology, 2022
Andrew Wei, Ahmed Hamed Salem, Deanna Brackman   +2 more
exaly  

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

International Journal of Molecular Sciences, 2022
Vladimir Vainstein, Boaz Nachmias, Adir Shaulov   +2 more
exaly  

Review of Venetoclax in CLL, AML and Multiple Myeloma

Journal of Personalized Medicine, 2021
Mary Ann Anderson, Masa Lasica, Anderson Mary Ann   +2 more
exaly  

Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway

International Immunopharmacology, 2022
Yan-Jie He, Yu-Xian Huang, Yu-Hua Li
exaly  

How do we manage t(11;14) plasma cell disorders with venetoclax?

British Journal of Haematology, 2022
Rajshekhar Chakraborty, , Suzanne Lentzsch   +2 more
exaly  

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

Cancers, 2023
Giovanni Palladini, Efstathios Kastritis, Hila Magen   +2 more
exaly  

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Oncologist, 2022
Pankit Vachhani, Esprit Ma, Melissa Montez   +2 more
exaly  

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Annals of Oncology, 2017
Jeffrey J Pu, Nicole Lamanna, B D Cheson   +2 more
exaly